FOXP3 Genetic Variation at Position -2383 C/T (rs3761549) in Patients with Breast Cancer

被引:0
|
作者
Shiri, Zahra [1 ]
Mansouri, Reza [1 ,2 ]
Haghshenas, Mohammad Reza [3 ]
Talei, Abdolrasoul [4 ,5 ]
Erfani, Nasrollah [3 ,6 ]
机构
[1] Shahid Sadoughi Univ Med Sci, Int Branch, Fac Med, Dept Immunol, Yazd, Iran
[2] Shahid Sadoughi Univ Med Sci, Hematol & Oncol Res Ctr, Yazd, Iran
[3] Shiraz Univ Med Sci, Sch Med, Shiraz Inst Canc Res, Shiraz, Iran
[4] Shiraz Univ Med Sci, Breast Dis Res Ctr, Shiraz, Iran
[5] Shiraz Univ Med Sci, Sch Med, Dept Surg, Shiraz, Iran
[6] Shiraz Univ Med Sci, Sch Med, Dept Immunol, Shiraz, Iran
关键词
Breast cancer; FOXP3; gene; Single nucleotide polymorphism; PCR-RFLP; RISK-FACTORS; T-CELLS; POLYMORPHISMS; EPIDEMIOLOGY; WOMEN; IPEX;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We investigated the possibility of an association between the C-2383T polymorphism (rs3761549) in the promoter region of the FOXP3 gene with breast cancer. Methods: The study groups consisted of 250 women diagnosed with breast cancer (case group) and 250 healthy women (control group). Polymerase chain reaction-restriction fragment length polymorphism was performed for genotyping. Results: Breast cancer cases had a C allele frequency of 455 (91%) and T allele frequency of 45 (9%). The control group had a C allele frequency of 468 (93.6%) and 32 (6.4%) for the T allele. The CC genotype was present in 206 (82.4%) patients, 43 (17.2%) patients had the CT genotype, and the TT genotype was observed in 1 (0.4%) patient. In the control group, 219 (87.6%) had the CC genotype, whereas 30 (12%) had the CT genotype, and 1 (0.4%) had the TT genotype. Statistical analysis revealed no significant differences in the distribution of alleles and genotypes between patients and controls (P>0.05). There was no significant association between genotype distribution and patients' clinicopathological factors. Conclusion: Our results do not support an association between the FOXP3 -2383 C/T polymorphism and breast cancer in a population from southern Iran.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 50 条
  • [41] Correlation Between FOXP3 mRNA Expression, Regulatory T-Cells (Tregs) in Peripheral Blood and Tumor Tissue, and Outcome in Patients With Breast Carcinoma
    Ortiz-Martinez, Fernando
    Sanmartin, Elena
    Pomares-Navarro, Eloy
    Martinez-Peinado, Pascual
    Sempere-Ortells, Jose
    Culianez, Ana
    Lerma, Enrique
    Aranda, F.
    Peiro, Gloria
    LABORATORY INVESTIGATION, 2015, 95 : 59A - 59A
  • [42] Heterozygous Genetic Variations of FOXP3 in Xp11.23 Elevate Breast Cancer Risk in Chinese Population via Skewed X-Chromosome Inactivation
    Zheng, Jian
    Deng, Jieqiong
    Jiang, Lan
    Yang, Lei
    You, Yonghe
    Hu, Min
    Li, Na
    Wu, Hongchun
    Li, Wei
    Li, Hongbin
    Lu, Jiachun
    Zhou, Yifeng
    HUMAN MUTATION, 2013, 34 (04) : 619 - 628
  • [43] FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial
    Ladoire, S.
    Mignot, G.
    Dalban, C.
    Chevriaux, A.
    Arnould, L.
    Rebe, C.
    Apetoh, L.
    Boidot, R.
    Penault-Llorca, F.
    Fumoleau, P.
    Roche, H.
    Spielmann, M.
    Levy, C.
    Lortholary, A.
    Eichler, F.
    Mesleard, C.
    Bonnetain, F.
    Ghiringhelli, F.
    ANNALS OF ONCOLOGY, 2012, 23 (10) : 2552 - 2561
  • [44] Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy
    Sylvain Ladoire
    Laurent Arnould
    Grégoire Mignot
    Bruno Coudert
    Cédric Rébé
    Fanny Chalmin
    Julie Vincent
    Mélanie Bruchard
    Bruno Chauffert
    François Martin
    Pierre Fumoleau
    François Ghiringhelli
    Breast Cancer Research and Treatment, 2011, 125 : 65 - 72
  • [45] Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy
    Ladoire, Sylvain
    Arnould, Laurent
    Mignot, Gregoire
    Coudert, Bruno
    Rebe, Cedric
    Chalmin, Fanny
    Vincent, Julie
    Bruchard, Melanie
    Chauffert, Bruno
    Martin, Francois
    Fumoleau, Pierre
    Ghiringhelli, Francois
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (01) : 65 - 72
  • [46] CD4+ T Cells Expressing Latency-Associated Peptide and Foxp3 Are an Activated Subgroup of Regulatory T Cells Enriched in Patients with Colorectal Cancer
    Mahalingam, Jayashri
    Lin, Chun-Yen
    Chiang, Jy-Ming
    Su, Po-Jung
    Chu, Yu-Yi
    Lai, Hsin-Yi
    Fang, Jian-He
    Huang, Ching-Tai
    Lin, Yung-Chang
    PLOS ONE, 2014, 9 (09):
  • [47] Cyclophosphamide induces dose dependent apoptosis of CD4+FoxP3+regulatory T cells relative to CD4+FoxP3-effector T cells in breast cancer patients
    Chen, Gang
    Leatherman, James M.
    Sunay, Melek Erdinc
    Emens, Leisha A.
    CANCER RESEARCH, 2013, 73 (08)
  • [48] The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer
    Noriko Goda
    Shinsuke Sasada
    Hideo Shigematsu
    Norio Masumoto
    Koji Arihiro
    Hiroyoshi Nishikawa
    Shimon Sakaguchi
    Morihito Okada
    Takayuki Kadoya
    Discover Oncology, 13
  • [49] Use of CD8 and Foxp3 immune infiltrates after neoadjuvant chemotherapy to predict survival in HER2-overexpressing breast cancer patients
    Ghiringhelli, F.
    Coudert, B. P.
    Arnould, L.
    Fumoleau, P.
    Ladoire, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Breast cancer stem cells convert anti-tumor CD4+T cells to pro-tumor T regulatory cells: Potential role of exosomal FOXP3
    Basak, Udit
    Chakraborty, Sourio
    Mukherjee, Sumon
    Pati, Subhadip
    Khan, Poulami
    Ghosh, Subhajit
    Adhikary, Arghya
    Jana, Kuladip
    Sa, Gaurisankar
    Das, Tanya
    CELLULAR IMMUNOLOGY, 2025, 409